Orrick Advises Tiziana on U.S. Follow-On Offering
| March.17.2020
Orrick’s Ed Lukins has advised biotech company Tiziana Life Sciences on its U.S. follow-on offering of 3,333,333 of American Depositary Shares (ADS) ...
Helping life
sciences
companies
innovate
and grow
Life Sciences Sector
Our Life Sciences practice is built around our core commitment to support the development of technology that improves lives.
Client Results
Orrick Advises Oisín Biotechnologies on Financing
| March.02.2020
Orrick has advised Seattle-based biotechnology company Oisín Biotechnologies on its $3 million pre-seed SAFE funding round.
Orrick Advises Cortexyme on $125 Million Private Placement
| February.11.2020
Orrick has advised San Francisco-based biopharmaceutical company Cortexyme (Nasdaq: CRTX) on its $125 million private placement of common stock.
Orrick Advises Inato on Series A Financing
| February.04.2020
Orrick has advised Paris-based startup Inato on its $14 million Series A financing round.
Orrick Advises Cerba in Acquisition of Curie
| November.21.2019
With this acquisition, Cerba HC Healthcare Italia consolidates its presence in the field of diagnostic imaging.
Gilead Wins Major Federal Circuit Ruling in Multi-Billion Dollar Patent Battle
| October.30.2019
Preserving a lower court ruling setting aside the largest patent verdict in history, an Orrick appellate team secured an important win for Gilead.
Orrick Advises Bayer on Acquisition of BlueRock Therapeutics
| August.08.2019
Orrick has advised Bayer on its acquisition of biotech company BlueRock Therapeutics. With Bayer currently holding a 40.8% stake, the investment ...
Orrick Advises Bayer on $250 Million Century Therapeutics Financing
| July.01.2019
Orrick has advised Leaps by Bayer in its $215 million investment commitment in Century Therapeutics.
Orrick Advises DURECT on $15 Million Registered Direct Offering
| June.24.2019
Orrick represented DURECT Corporation in its registered direct offering of 29,000,000 shares of common stock.
Orrick Advises Cortexyme on $75 Million IPO
| May.09.2019
Orrick has advised San Francisco-based biopharmaceutical company Cortexyme on its $75 million initial public offering of 4.412 million shares of ...
Insights
Dusting the Regulatory Framework – French Competition Authority Seeks to Liberalize Distribution of Drugs and Private Medical Biology
by Marie-Laure Combet and Elise Durand | April.26.2019
On April 4, 2019, just three months after the publication of the European Commission (EC) report on “Competition enforcement in the pharmaceutical ...
Profiles in Innovation: Twist Bioscience’s Co-Founder Navigates Company from Start-up to Public Company
| February.21.2019
Emily Leproust discusses her inspiration and journey building a public company in the fast growing synthetic DNA market with commentary from Orrick ...
Scope of Estoppel Post-IPR Proceedings Becoming Clearer
by K. Patrick Herman | March.27.2017
This estoppel provision has been the subject of a number of Federal Circuit and district court decisions.
HALLOWEEN TREAT: Judge’s October 31 Order Adds $21 Million to Jury’s $70 Million Award for Trade Secret Theft
by Mona S. Amer | November.22.2016
On October 31st of this year, a district judge in Massachusetts granted a motion for enhanced damages in a theft of trade secrets case, adding an ...
Confidential Settlement Amounts Are Not Necessarily Confidential
| June.10.2016
Courts in the Northern District of California, which have been handling price-fixing class actions in the electronics industry for more than a ...
Supreme Courts Request for Views of the United States on Cert Petition in Lamictal ReversePayment C
by Robert Reznick | June.09.2016
On Monday, June 7, the Supreme Court requested the views of the Solicitor General in connection with a petition for certiorari filed by the U.S. ...
Third Circuit Rejects Drug Manufacturer’s Single-Product Bundling Claim – But Prescription for the Future Is Unclear
by Russell P. Cohen and Howard Ullman | May.19.2016
You know what they say: one man’s price is another man’s bundle. No? Well maybe they should, after this recent decision out of the Third Circuit in ...
Quo Vadis FTC: What Does the Commission's Complaint Against Endo Pharmaceuticals and Others Say About the Future of Post-Actavis Hatch-Waxman Litigation and Reverse Payment Settlements?
by Robert Reznick | April.07.2016
This alert, the title of which is adapted from a March 30, 2016 FTC Staff Attorney blog post, considers the FTC’s first lawsuit challenging a ...
Post-Grant Proceedings Complicate Pharmaceutical Litigation
| April.04.2016
Since the passage of the America Invents Act in 2011, various changes to the patent litigation landscape have occurred.
District Court Finds No Personal Jurisdiction over Swedish Manufacturer of Pharmaceutical Product That Knew its Products Were Resold to U.S. Customers
| January.05.2016
Novotec Pharma LLC, v. Glycobiosciences, Inc., U.S. District Court for the District of New Jersey, January 5, 2016
The complicated history of this ...
Eight Product-Hopping Takeaways from Namenda Ruling
by Robert Reznick and Howard Ullman | June.11.2015
Orrick attorneys co-author an article on the Second Circuit's affirmation of a preliminary injunction in New York v. Actavis and what aspects of the ...
News
Orrick Adds Corporate Advisor Ed Lukins in London
| September.18.2019
Orrick announced today that leading corporate advisor Ed Lukins has joined the firm as a partner based in London. He joins from Cooley, where he ...
Orrick Recruits Life Sciences & Tech Advisor Gregg Griner to Lead Boston Corporate Practice
| September.04.2019
Continuing the growth of Orrick’s Boston office, the firm announced today that Life Sciences and Technology advisor Gregg Griner has joined the firm ...
Orrick Grows Life Sciences Team
| April.09.2019
Orrick announced today that Stephen Thau, a leading advisor to life sciences and other tech companies, has joined the firm as a partner, based in ...
Antitrust Watch Blog
In-depth analysis and commentary on major developments in global antitrust and competition law
"Enjoys a fine reputation for its work in the technology and life sciences arenas.”
2016 Chambers USA - Capital Markets (California)
The World in U.S. Courts
A quarterly review of the most important decisions applying U.S. law to global business and cross-border activities.
Some of the recognition we have received
IP Group of the Year
Law360, 4 times
Tech Group of the Year
Law360, 2018 and 3 times
Employment Group of the Year
Law360, 2018 and 3 times
Recommended
Global Competition Review 100, 2019
IP Litigation Department of the Year
The American Lawyer, 2016
Top 5 Litigation Powerhouse
Law360, 2016
Litigation Power Rankings – Top 10
The American Lawyer, 2016
Appellate Hot List
National Law Journal, 2018 and 7 times
Litigation Department of the Year
The Recorder, 2016 and 2 times
Labor & Employment Defense Firm of the Year
The Recorder, 2017 and 4 times
International IP Firm of the Year
China Law & Practice, 2015
Tier 1 for China Patent Work
Asian Legal Business, 2013-2018
China Foreign Law Firm of the Year
Managing IP, 2016